Page last updated: 2024-09-05

sorafenib and ilexgenin a

sorafenib has been researched along with ilexgenin a in 1 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (ilexgenin a)	Trials (ilexgenin a)	Recent Studies (post-2010) (ilexgenin a)
6,520	730	5,251	15	0	14

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dai, XJ; Fan, JH; Liu, C; Liu, Q; Shen, YJ; Sun, WD; Sun, Y; Wang, J; Yang, H; Zhang, YQ; Zhao, JX	1

Other Studies

1 other study(ies) available for sorafenib and ilexgenin a

Article	Year
Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicology and applied pharmacology, 2017, Jan-15, Volume: 315 Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Sorafenib; STAT3 Transcription Factor; Triterpenes	2017

Article

Year

Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.

Toxicology and applied pharmacology, 2017, Jan-15, Volume: 315

Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Sorafenib; STAT3 Transcription Factor; Triterpenes

2017